Know Cancer

forgot password

A Randomized, Placebo Controlled Clinical Trial of SOM230 (Pasireotide LAR) In Severe Polycystic Liver Disease

Phase 2
18 Years
Open (Enrolling)
Somatostatin Analogs, Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney Disease, Autosomal Dominant Polycystic Liver Disease

Thank you

Trial Information

A Randomized, Placebo Controlled Clinical Trial of SOM230 (Pasireotide LAR) In Severe Polycystic Liver Disease

Pasireotide (SOM230) is a novel multi-receptor-targeted analog that has high affinity for
four of the five SST receptor subtypes (SSTr1, SSTr2, SSTr3 and SSTr5); it has a 40-fold
higher affinity and 158-fold higher functional activity for the SST5 receptor than
octreotide. Because of its broad receptor binding profile, pasireotide may be more potent in
Polycystic Liver Disease (PLD) than octreotide. In this randomized double blind placebo
controlled trial the investigators will compare SOM230 treatment to placebo for 12 months in
patients with PLD. The primary endpoints will be assessed at 12 months and patients
receiving placebo then crossed over to SOM230, permitting all participants to receive SOM230
for the subsequent two years. Magnetic resonance imaging (MRI) will be used to assess liver
volume - the primary endpoint, which will be assessed at baseline, end of years 1 and 3.
This study will assess the efficacy and safety of SOM230 in reducing total liver volume and
improving quality of life over 12 months. (The investigators will not be assessing efficacy
at 24 months.) The therapy way be effective in PLD but also may prove to be effective for
many more patients with Polycystic Kidney Disease (PKD) which will be evaluated using eGFR
and kidney volume using MRI.

The investigators plan to add other sub-sites in other locations.

Inclusion Criteria:

- Male or female Age ≥ 18 years.

- Diagnosis of PLD associated with ADPKD (meeting the Modified Ravine's criteria) or
isolated ADPLD (defined by the criteria described by Reynolds et al)

- Severe PLD defined as a liver volume >4000mL or symptomatic disease due to mass
effects from hepatic cysts (must be able to undergo MRI or CT scan to determine

- Not a candidate for or declining surgical intervention.

- Capable of providing informed consent.

- Life expectancy ≥ 12 weeks

- Patients with a known history of impaired fasting blood glucose (glucose >100 and
<126) may be included at the discretion of the PI. These patients should be monitored
closely throughout the trial and antihyperglycemic treatment adjusted as necessary.
Patients that are deemed non eligible due to elevated glucose can be re-screened
after adequate medical treatment.

- Adequate end organ function as defined by:

- Adequate bone marrow function:

- WBC ≥ 2.5 x 109/L

- Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L

- Platelets ≥ 100 x 109/L

- Hb ≥ 9 g/dL

- No evidence of significant liver disease:

- Serum bilirubin ≤1.5 x ULN

- INR < 1.3

- ALT and AST ≤ 2 x ULN

- Estimated glomerular filtration rate (eGFR) >30 ml/min/m2

- Serum amylase and lipase ≤ 1.5 x ULN

- Alkaline phosphatase ≤ 2.5 x ULN

- Written informed consent obtained prior to any screening procedures

- Willingness and ability to comply with scheduled visits, treatment plans, laboratory
tests and other study procedures

Exclusion Criteria:

- Patients will be considered ineligible for this study if they meet any of the
following criteria:

- Patients with a known hypersensitivity to SST analogs or any component of the
pasireotide LAR or SQ formulations.

- Patients with known malabsorption syndrome, short bowel or chologenic diarrhea not
controlled by specific therapeutic means.

- Patients with abnormal coagulation (PT or a PTT elevated by 30% above normal limits).

- Patients on continuous anticoagulation therapy. Patients who were on anticoagulant
therapy must complete a washout period of at least 10 days and have confirmed normal
coagulation parameters before study inclusion.

- Patients with symptomatic cholelithiasis.

- Patients who are not biochemically euthyroid.

- Patients with known history of hypothyroidism are eligible if they are on adequate
and stable re-placement thyroid hormone therapy for at least 3 months.

- Serum magnesium ≥ ULN

- QT-related exclusion criteria:

- QTcF at screening > 470 msec

- Patients with a history of syncope or family history of idiopathic sudden death

- Patients who have sustained or clinically significant cardiac arrhythmias

- Risk factors for Torsades de Pointes such as hypokalemia, hypomagnesemia, cardiac
failure, clinically significant/symptomatic bradycardia, or high-grade AV block

- Patients with concomitant disease(s) that could prolong QT such as autonomic
neuropathy (caused by diabetes, or Parkinson's disease), HIV, cirrhosis, uncontrolled
hypothyroidism or cardiac failure

- Family history of long QT syndrome

- Concomitant medications known to prolong the QT interval.

- Potassium < or = to 3.5

- Patients who have any severe and/or uncontrolled medical conditions or other
conditions that could affect their participation in the study such as:

- Patients who have Uncontrolled diabetes as defined by HbA1c>8%* despite adequate

- Patients with the presence of active or suspected acute or chronic uncontrolled
infection or with a history of immunodeficiency, including a positive HIV test result
(ELISA and Western blot). An HIV test will not be required; however, previous medical
history will be reviewed.

- Non-malignant medical illnesses that are uncontrolled or whose control may be
jeopardized by the treatment with this study treatment.

- Liver disease such as cirrhosis, decompensated liver disease, chronic active
hepatitis or chronic persistent hepatitis.

- Baseline ALT or AST >3x ULN

- Patients with life-threatening autoimmune and ischemic disorders.

- Uncontrolled hypertension

- Patients who have a history of a primary malignancy, with the exception of locally
excised non-melanoma skin cancer and carcinoma in situ of uterine cervix. (Patients
who have had no evidence of disease from primary cancer for 3 or more years are
allowed to participate in the study.)

- History of pancreatitis

- Patients with a known history of hepatitis B or C

- Presence of Hepatitis B surface antigen (HbsAg)

- Presence of Hepatitis C antibody (anti-HCV)

- Patients with a history of, or current, alcohol misuse/abuse within the past 12

- Known gallbladder or bile duct disease, acute or chronic pancreatitis

- Patients who have any current or prior medical condition that may interfere with the
conduct of the study or the evaluation of its results in the opinion of the
Investigator or the Sponsor's Medical Monitor

- Use of an investigational drug within 1 month prior to dosing

- Patients with a history of non-compliance to medical regimens or who are considered
potentially unreliable or will not be able to complete the entire study

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Outcome Measure:

Absolute change in liver volume

Outcome Description:

MRI will be used to measure liver volume.

Outcome Time Frame:

baseline to month 12

Safety Issue:


Principal Investigator

Marie C Hogan, MD PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Mayo Clinic


United States: Data and Safety Monitoring Board

Study ID:




Start Date:

August 2012

Completion Date:

December 2016

Related Keywords:

  • Somatostatin Analogs
  • Polycystic Liver Disease
  • Autosomal Dominant Polycystic Kidney Disease
  • Autosomal Dominant Polycystic Liver Disease
  • Polycystic Liver Disease
  • Autosomal dominant polycystic kidney disease
  • Autosomal dominant polycystic liver disease
  • Somatostatin analogs
  • Pasireotide LAR
  • SOM230
  • Kidney Diseases
  • Polycystic Kidney Diseases
  • Liver Diseases
  • Polycystic Kidney, Autosomal Dominant
  • Cysts



Mayo ClinicRochester, Minnesota  55905